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Clinical outcomes, not clinical utility, should  
be the major consideration for saxagliptin  
with or without metformin
Sheila A Doggrell
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Faculty of Health, Queensland 
University of technology,  
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Dear editor,
A recent review by Panagoulias and Doupis, published in Patient Preference and 
Adherence, concerned the saxagliptin/metformin fixed combination (SAXA/MET 
FDC), and was titled “Clinical utility in the treatment of type 2 diabetes with the 
saxagliptin/metformin fixed combination.”1 This review concluded that “The 
SAXA/MET FDC is a patient-friendly, dosage-flexible, and hypoglycemia-safe regi-
men with very few adverse events and a neutral or even favorable effect on body 
weight. It achieves significant glycosylated hemoglobin A
1c 
reduction helping the 
patient to achieve his/her individual glycemic goals.”1
Although these conclusions about saxagliptin are reasonable, in my opinion 
this review seems to have put too much emphasis on clinical utility and not enough 
emphasis on the clinical outcomes of cardiovascular safety and efficacy. For the 
 subject with type 2 diabetes, the ultimate goal is to reduce cardiovascular outcomes, 
and in this, achieving glycemic control is just a surrogate endpoint. Metformin has 
been shown to improve cardiovascular outcomes in subjects with type 2 diabetes. 
However, saxagliptin alone, or in combination with metformin has not been shown 
to improve clinical outcomes.
For metformin, improved cardiovascular outcomes were shown in the UK 
 Prospective Diabetes Study (UKPDS) 34.2 In this study, 342 overweight subjects 
with type 2 diabetes were assigned intensive control treatment with metformin, which 
was 850 mg/day, then 850 mg twice daily, and 1,700 mg in the morning followed 
by 850 mg with the evening dose. Subjects were allowed to reduce their dose of met-
formin, if symptoms of diarrhea or nausea occurred. This intensive treatment with 
metformin was compared with the conventional treatment of diet. After about 10 years, 
subjects taking metformin had a 32% reduction of developing any diabetes-related 
endpoint, which included macrovascular and microvascular complications, compared 
to subjects who were not treated with anti-diabetes drugs.2
Even for metformin, it is not clear whether the findings of UKPDS-34 apply to 
the dose and preparation of metformin being used in SAXA/MET FDC. Thus, the 
findings in UKPDS-34, with metformin, are with the conventional rather than the 
extended release preparation, and are only applicable to the dose used, which is not 
given. When metformin hydrochloride extended release is used alone, in  Australia, the 
initial dose is 500 mg once daily, which can be increased up to 2 g. When metformin 
hydrochloride extended release is combined with saxagliptin, the doses available 
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are 500, 850, or 1,000 mg/day. Without testing of these doses 
of extended release metformin in clinical trial, it is not known 
whether they are high enough to have the clinical benefits 
observed in UKPDS-34. Thus, it cannot be assumed that the 
doses of metformin extended release, which have been com-
bined with saxagliptin, are improving clinical outcomes.
Most trials with saxagliptin have been comparator trials 
with other anti-diabetes medicines with surrogate endpoints 
such as HbA
1c
. Similarly, surrogate endpoints have been 
the major outcomes for trials on saxagliptin as add-on or 
combination treatment with metformin. These trials are not 
discussed as they do not have clinical outcomes.
The only trial to determine cardiovascular endpoints 
with saxagliptin is the cardiac safety trial: SAVOR-TIMI 53 
(Saxagliptin Assessment of Vascular Outcomes Recorded in 
Patients with Diabetes Mellitus-Thrombolysis in Myocardial 
Infarction 53 trial). In SAVOR-TIMI 53, saxagliptin 5 mg was 
compared to placebo, in subjects with type 2  diabetes, 70% of 
whom were taking metformin.3 At the time that the review by 
Panagoulias and Doupis went to press, the only information 
available, from SAVOR-TIMI 53, was a paragraph, from 
the company,4 and the supporting data were not supplied. 
This paragraph was paraphrased by Panagoulias and Doupis 
as “Preliminary data have shown that SAXA have met the 
primary safety objective of noninferiority; but did not meet 
the primary efficacy objective of superiority for a composite 
end point of cardiovascular death, nonfatal myocardial infarc-
tion, or nonfatal ischemic stroke, when added to the patient’s 
current standard of care (with or without other antidiabetic 
therapies) compared to placebo.”1
SAVOR-TIMI 53 has recently been published in 
the New England Journal of Medicine,3 and the data 
supports the paragraph paraphrased above. However, 
analysis of the individual items in this trial show they were 
similar in  saxagliptin 5 mg and placebo group, except for 
 hospitalization for heart failure, which was 27% higher 
in the saxagliptin group (3.5%) than the placebo group 
(2.8%, P=0.007).3 This is not mentioned in the  company’s 
web  summary.4 A recent meta-analysis presented to 
the Australasian Society of Experimental and Clinical 
 Pharmacologists and Toxicologists, reported that dipeptidyl 
peptidase-4 inhibitors had no effect on all-cause mortality, 
cardiovascular mortality, myocardial infarction, stroke, but 
significantly increased hospitalization for heart failure.5 
Thus, the cardiovascular safety of saxagliptin and other 
dipeptidyl peptidase-4  inhibitors alone has not been 
established.
In conclusion, although clinical utility is important for 
medicines used in diabetes, it should not be forgotten that 
improved clinical outcomes are the ultimate goal. These have 
not been shown for saxagliptin alone, or in combination with 
metformin. It is also important to firmly establish the cardio-
vascular safety of saxagliptin, and this has not been achieved 
to date. In my opinion, these points should have been empha-
sized in the review by Panagoulias and Doupis.1
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Dear editor,
In response to the letter from Doggrell commenting on our 
recently authored paper titled “Clinical utility in the treat-
ment of type 2 diabetes with the saxagliptin/metformin fixed 
combination,”1,2 I completely agree with Doggrell that clini-
cal outcomes should be the major consideration, not only 
for the treatment with saxagliptin or saxagliptin/metformin 
combination, but also for the treatment with other diabetes 
related oral or injectable agents. However, the aim of this 
review paper was to focus on “the clinical utility of the 
saxagliptin/metformin combination.” It was an invited review 
paper, thus, we mainly focused on the requested topic which 
would actually fit better to the scope of the journal Patient 
Preference and Adherence.
Indeed, SAVOR-TIMI 53 (Saxagliptin Assessment of 
Vascular Outcomes Recorded in Patients with Diabetes 
Mellitus-Thrombolysis in Myocardial Infarction 53 trial) 
results had not yet been published by the time we 
 finished our work and we thank Doggrell for pointing 
out the main points of this study.3 Relative to the topics 
addressed by Doggrell regarding cardiovascular safety of 
the DPP-4 inhibitors, I would like also to add, that prov-
ing cardiovascular safety does not necessarily mean that 
DPP-4 inhibitors provide cardiovascular protection as well. 
In the meta-analysis by Wu et al DPP-4 inhibitors did not 
provide cardiovascular protection, their use resulted in no 
effect on cardiovascular mortality, myocardial infarction 
and stroke.4 The increased rate of heart failure related hos-
pitalization, along with the one reported for saxagliptin in 
the SAVOR-TIMI 53 trial, should be further investigated.3,4 
To this direction, given that cardiac failure is a multifac-
torial condition, I believe, that more large and long-term 
prospective studies should be conducted in order to fully 
reveal the relationship between the cardiovascular system 
and the use of DPP-4 inhibitors.
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